enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Recommendation of “Hold” from Brokerages

enGene Holdings Inc. (NASDAQ:ENGN) has earned a consensus recommendation of “Hold” from the fourteen analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $12.6818.

A number of equities analysts have commented on ENGN shares. Leerink Partners lowered shares of enGene from an “outperform” rating to a “market perform” rating and set a $2.00 price objective on the stock. in a report on Friday, May 8th. Weiss Ratings lowered shares of enGene from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 15th. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $2.00 target price (down from $25.00) on shares of enGene in a research report on Friday, May 8th. Raymond James Financial lowered enGene from a “strong-buy” rating to an “outperform” rating and set a $4.00 target price on the stock. in a research report on Friday, May 8th. Finally, Morgan Stanley lowered enGene from an “overweight” rating to an “equal weight” rating in a research report on Friday, May 8th.

enGene Stock Performance

Shares of ENGN stock opened at $1.65 on Tuesday. enGene has a 12 month low of $1.40 and a 12 month high of $12.25. The company has a debt-to-equity ratio of 0.09, a current ratio of 11.75 and a quick ratio of 11.75. The firm has a market capitalization of $110.53 million, a P/E ratio of -0.73 and a beta of -0.29. The company’s fifty day moving average price is $4.80 and its two-hundred day moving average price is $7.38.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Monday, March 9th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.11. On average, research analysts anticipate that enGene will post -2.02 earnings per share for the current fiscal year.

Institutional Investors Weigh In On enGene

Institutional investors have recently modified their holdings of the stock. Privium Fund Management B.V. acquired a new stake in shares of enGene in the 4th quarter valued at about $3,179,000. Braidwell LP acquired a new stake in enGene during the third quarter worth about $15,479,000. PFS Partners LLC raised its stake in enGene by 22.2% during the fourth quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock worth $99,000 after acquiring an additional 2,000 shares during the period. Hudson Bay Capital Management LP acquired a new stake in enGene during the third quarter worth about $76,000. Finally, Monashee Investment Management LLC raised its stake in enGene by 8.5% during the first quarter. Monashee Investment Management LLC now owns 320,000 shares of the company’s stock worth $2,179,000 after acquiring an additional 25,000 shares during the period. Institutional investors and hedge funds own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.